Handelsbanken Fonder Ab Cassava Sciences Inc Transaction History

Handelsbanken Fonder Ab

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 28, 2023	BUY	$23.46 - $36.44 $11,730 - $18,220	500 Added 5.38%	9,800 $236,000
Q4 2022 Feb 07, 2023	SELL	$27.82 - $44.16 $19,474 - $30,911	-700 Reduced 7.0%	9,300 $275,000
Q2 2022 Aug 03, 2022	SELL	$17.22 - $38.47 $3,444 - $7,694	-200 Reduced 1.96%	10,000 $281,000
Q4 2021 Feb 08, 2022	SELL	$36.77 - $90.91 $158,111 - $390,913	-4,300 Reduced 29.66%	10,200 $446,000
Q3 2021 Nov 10, 2021	BUY	$41.79 - $135.3 $4,179 - $13,530	100 Added 0.69%	14,500 $900,000
Q2 2021 Aug 03, 2021	BUY	$32.15 - $89.72 $462,960 - $1.29 Million	14,400 New	14,400 $1.23 Million

195

13.7M

2.98M

6.57M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $101M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

Stay updated on Handelsbanken Fonder Ab with notifications on news.